AKT1 and cancer: Overall, the results suggest that RRM2 acts as a pro-oncogenic molecule and may promote the progression of PTC by activating the PI3K/Akt signaling pathway, regulating key proteins of the cell cycle, and inducing the EMT process, which is in high agreement with previous findings in other malignant tumors.